WuXi Biologics (Cayman) Inc. disclosed fresh capital-market activity covering both a targeted share repurchase and a marginal option-driven issuance, according to its Next Day Disclosure Return filed on 1 June 2026.

Share issuance • On 1 June 2026, 2,081 new ordinary shares were issued upon exercise of options granted under the company’s Pre-IPO Share Option Scheme (adopted 5 January 2016 and amended 10 August 2016). • The exercise price was HK$2.64 per share, adding 0.00005% to the share base. • Outstanding shares rose from 4.14091 billion to 4.14091 billion (4,140,912,517 shares).

Repurchase activity • On 1 June 2026 the company bought back 1,448,500 shares on the Hong Kong Stock Exchange at prices between HK$33.70 and HK$34.96, spending HK$49.91 million in aggregate. • These shares are intended for cancellation and equate to 0.035% of the issued share capital prior to the transaction. • Including purchases on 27–29 May (1.47 million, 1.53 million and 1.51 million shares respectively), a total of 5.96 million shares are currently pending cancellation, representing approximately 0.14% of the existing share count.

Repurchase mandate status • The current mandate, approved on 6 June 2025, authorises repurchases of up to 406.87 million shares. • Cumulative repurchases under this mandate have reached 29.14 million shares, or 0.72% of the company’s issued share base at the date of mandate approval. • Under Hong Kong Listing Rules, WuXi Biologics is restricted from issuing new shares for 30 days following the latest buyback, setting a moratorium until 1 July 2026.

Capital structure snapshot (post-transactions, prior to cancellation of repurchased shares) • Issued shares: 4.14 billion • Treasury shares: none

The board confirmed that all activities complied with Hong Kong Stock Exchange listing rules and relevant legal requirements.